Last reviewed · How we verify
NCT04949776: AITIC
Artificial Intelligence in Breast Cancer Screening Programs
NA trial testing Mammograms in Breast Cancer in 31,301 participants. Completed in 11 January 2024.
11 January 2024
Quick facts
| Lead sponsor | Maimónides Biomedical Research Institute of Córdoba |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 31,301 |
| Start date | 15 March 2022 |
| Primary completion | 11 January 2024 |
| Estimated completion | 11 January 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Mammograms
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Screening — all drugs for Screening →
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Who can join
Adults 50 to 71, female only, with Breast Cancer or Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The use of artificial intelligence software in breast screening (Transpara®) makes it possible to identify studies with a very low probability of cancer. The hypothesis raised in this work is that reading strategies based on artificial intelligence (single or double reading only of cases with a score\> 7 with Transpara®), allow reducing the workload of a screening program by more than 50 % with respect to the standard reading of the program (double reading of all cases without Transpara®), without presenting inferiority in terms of detection rates and recalls of the program, both with the use of 2D digital mammography and with the use of tomosynthesis or 3D mammogram.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Deep learning in breast imaging.
Bhowmik A, Eskreis-Winkler S. · · 2022 · cited 20× · PMID 36105427 · DOI 10.1259/bjro.20210060 -
AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial.
Elías-Cabot E, Romero-Martín S, Raya-Povedano JL, Rodríguez-Ruiz A, et al · · 2026 · PMID 41857202 · DOI 10.1038/s41591-026-04277-x
Verify or expand the search:
- PubMed search for NCT04949776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Maimónides Biomedical Research Institute of Córdoba trials
Trials by the same sponsor.
- NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
- NCT07479303 — Vitamin D Status in Young Medical Residents · completed
- NCT07178379 — Hysteroscopy Anesthesia for Relief of Pain · NA · not yet recruiting
- NCT06712485 — Biomarkers in EV Associated With Marrow Adiposity in Anorexia · not yet recruiting
- NCT06579846 — 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04949776 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maimónides Biomedical Research Institute of Córdoba
- Last refreshed: 14 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04949776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing